Browse AATF

Summary
SymbolAATF
Nameapoptosis antagonizing transcription factor
Aliases DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus, nucleolus
Domain PF13339 Apoptosis antagonizing transcription factor
PF08164 Apoptosis-antagonizing transcription factor
Function

May function as a general inhibitor of the histone deacetylase HDAC1. Binding to the pocket region of RB1 may displace HDAC1 from RB1/E2F complexes, leading to activation of E2F target genes and cell cycle progression. Conversely, displacement of HDAC1 from SP1 bound to the CDKN1A promoter leads to increased expression of this CDK inhibitor and blocks cell cycle progression. Also antagonizes PAWR mediated induction of aberrant amyloid peptide production in Alzheimer disease (presenile and senile dementia), although the molecular basis for this phenomenon has not been described to date.

> Gene Ontology
 
Biological Process GO:0006801 superoxide metabolic process
GO:0007346 regulation of mitotic cell cycle
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0010559 regulation of glycoprotein biosynthetic process
GO:0010561 negative regulation of glycoprotein biosynthetic process
GO:0022613 ribonucleoprotein complex biogenesis
GO:0032928 regulation of superoxide anion generation
GO:0032929 negative regulation of superoxide anion generation
GO:0040016 embryonic cleavage
GO:0042254 ribosome biogenesis
GO:0042554 superoxide anion generation
GO:0042982 amyloid precursor protein metabolic process
GO:0042983 amyloid precursor protein biosynthetic process
GO:0042984 regulation of amyloid precursor protein biosynthetic process
GO:0042985 negative regulation of amyloid precursor protein biosynthetic process
GO:0072593 reactive oxygen species metabolic process
GO:0090322 regulation of superoxide metabolic process
GO:1903018 regulation of glycoprotein metabolic process
GO:1903019 negative regulation of glycoprotein metabolic process
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000378 negative regulation of reactive oxygen species metabolic process
Molecular Function GO:0030275 LRR domain binding
GO:0043522 leucine zipper domain binding
GO:0048156 tau protein binding
Cellular Component GO:0005813 centrosome
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-204998: Cell death signalling via NRAGE, NRIF and NADE
R-HSA-193648: NRAGE signals death through JNK
R-HSA-162582: Signal Transduction
R-HSA-166520: Signalling by NGF
R-HSA-193704: p75 NTR receptor-mediated signalling
Summary
SymbolAATF
Nameapoptosis antagonizing transcription factor
Aliases DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AATF and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolAATF
Nameapoptosis antagonizing transcription factor
Aliases DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AATF in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.59 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolAATF
Nameapoptosis antagonizing transcription factor
Aliases DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AATF in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1660.516
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3970.863
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0060.997
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1210.665
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1690.936
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0610.982
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1240.726
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0790.961
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1530.933
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1250.0128
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AATF in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAATF
Nameapoptosis antagonizing transcription factor
Aliases DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AATF. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAATF
Nameapoptosis antagonizing transcription factor
Aliases DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AATF. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AATF.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAATF
Nameapoptosis antagonizing transcription factor
Aliases DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AATF. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAATF
Nameapoptosis antagonizing transcription factor
Aliases DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AATF expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAATF
Nameapoptosis antagonizing transcription factor
Aliases DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AATF and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAATF
Nameapoptosis antagonizing transcription factor
Aliases DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AATF collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.